MEDEPOCH

WIPO WIPO 2020

Protect this trademark from copycats!

With our trademark monitoring alerts, you are automatically notified by email about copycats and free riders.

The International trademark MEDEPOCH was filed as Word mark on 06/08/2020 at the World Intellectual Property Organization.

Trademark Details Last update: February 24, 2023

Trademark form Word mark
File reference 1558883
Countries Australia Canada China European Community United Kingdom India Japan North Korea New Zealand Singapore
Base trademark US No. 88773853, January 27, 2020
Application date June 8, 2020
Expiration date August 9, 2021

Trademark owner

17301 W. Colfax Avenue,
Suite 152
US

Trademark representatives

3000 K Street, N.W., Sixth Floor Washington DC 20007 US

goods and services

09 Software in the fields of healthcare, medicine and wellness for use in patient communication, patient care, dynamic collection of patient related health and wellness data, care coordination and care management, chronic disease management, remote patient monitoring and engagement between health care providers and patients; downloadable electronic reports featuring health information, health data analysis and clinical insights; downloadable application programming interface (API) software; providing an interactive web-based and mobile application featuring technology that enables care providers and users to enter, access, track, monitor and generate health and medical information and reports (term considered too vague by the International Bureau - rule 13 (2) (b) of the Regulations)
10 Wearable medical device for monitoring vital signs, heart rate, respiratory rate, body position, activity level, gait, temperature, quality of sleep, motion and symptomatic events in the nature of coughing, sneezing, vomiting, and fall detection; providing medical device hardware and software, sold as a unit, for recording, transmitting, analyzing and reporting patient health data and clinical insights to care providers (term considered too vague by the International Bureau - rule 13 (2) (b) of the Regulations)
42 Data-as-a-service (DaaS) services featuring software for collection, verification, aggregation, storage, management, distribution, transmission and visualization of health-related data; software as a service (SaaS) services featuring software for integrating and analyzing patient health data for predictive analysis of health risks and health events; providing an interactive web platform featuring technology that enables care providers and users to enter, access, track, monitor and generate health and medical information and reports (term considered too vague by the International Bureau - rule 13 (2) (b) of the Regulations); providing a (computer software) cloud-based analytics platform for recording, transmitting, analyzing and reporting patient health data and clinical insights to care providers (term considered too vague by the International Bureau - rule 13 (2) (b) of the Regulations); platform as a service (PaaS) featuring a computer software platform in the fields of healthcare, medicine and wellness for patient communication, patient care, dynamic collection of patient related health and wellness data, care coordination and care management, chronic disease management, remote patient monitoring and engagement between health care providers and patients; software as a service (SaaS) featuring software in the fields of healthcare, medicine and wellness for the purpose of providing an integrated health management system using machine learning and artificial intelligence, namely, software for providing patients and health care providers access to patient information and data, for dynamic collection of patient related health and wellness data and for providing patients access to personalized information relevant to patient health and wellbeing; providing electronic reports in the field of early identification, detection and screening of adverse health events, health trends and complex health conditions via online non-downloadable software; providing temporary use of on-line non-downloadable Software as a Medical Device (SaMD) used as a diagnostic tool for early identification, detection and screening of adverse health events, health trends and complex health conditions; providing temporary use of on-line algorithmic non-downloadable software that analyzes, tracks and reports health data to allow medical professionals to determine courses of treatment and initiate proactive interventions and providing electronic reports associated therewith

Trademark history

Date Document number Area Entry
August 30, 2022 2022/40 Gaz NZ RAW: Rule 18ter(2)(ii) GP following a provisional refusal
April 8, 2022 2022/26 Gaz US RAW: Total Ceasing Effect
February 18, 2022 2022/9 Gaz CA Rejection
January 1, 2022 2022/2 Gaz SG Rejection
October 7, 2021 2021/40 Gaz JP Rejection
May 25, 2021 2021/23 Gaz EM RAW: Rule 18ter(2)(ii) GP following a provisional refusal
May 15, 2021 2021/20 Gaz GB RAW: Rule 18ter(2)(ii) GP following a provisional refusal
May 3, 2021 2021/18 Gaz IN Rejection
March 4, 2021 2021/10 Gaz CN Rejection
March 4, 2021 2021/10 Gaz NZ Rejection
January 13, 2021 2021/3 Gaz SG Rejection
December 18, 2020 2020/52 Gaz GB Rejection
December 2, 2020 2020/50 Gaz AU Rejection
November 24, 2020 2020/49 Gaz EM Rejection
June 8, 2020 2020/43 Gaz US Registration

ID: 141558883